Autopsy report · NCT02902731
Giant Cell Arteritis and Anakinra Trial
Cause of deathDrug or device supply
“experimental treatment no longer available”
Life of this trial
- Registered 10 months before it started.
- Ran for about 5 years 6 months before it stopped.
- 30 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- University Hospital, Caen
- Sponsor type
- University, hospital or other
- Conditions
- Giant Cell Arteritis
- Interventions
- PLACEBO; ANAKINRA
- Participants
- 30
- Sites
- 1
- Countries
- France
Trials that died the same way
- Phase II Study of TPA Plus Dexamethasone & CMT in Hematologic Malignancies
“Study was terminated early due to lack of experimental medication (supply issues)” - Molar Sodium Lactate Filling in Severe Meningeal Hemorrhage
“The treatments are no longer available.” - A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors
“Study was prematurely discontinued due to unacceptable toxicity.” - Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors
“The study was terminated since there was no need for further safety or efficacy data to be collected. The participants having benefit from the investigational treatments have been moved to a continuation study (NCT05059522)” - Study of Combination of Cetuximab and Radiotherapy Added to the Standard Treatment for Oesophageal Adenocarcinoma
“Experimental treatment not feasible due to high rate of drop out”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.